Comments on: What You Need To Know About The West Nile Virus http://www.thehealthblog.net/news/what-you-need-to-know-about-the-west-nile-virus/ A healthy body and a sound mind Thu, 29 Sep 2011 23:56:16 +0000 hourly 1 http://wordpress.org/?v=3.3.1 By: David Moskowitz MD FACP http://www.thehealthblog.net/news/what-you-need-to-know-about-the-west-nile-virus/comment-page-1/#comment-1253 David Moskowitz MD FACP Sun, 17 Aug 2008 22:15:11 +0000 http://www.thehealthblog.net/?p=269#comment-1253 GenoMed, a genomics-based Disease Management company in St. Louis, has had encouraging results treating West Nile virus encephalitis since 2003. We’ve had 82% treatment success rate in people (23 of 28 improved), 75% in horses (6 of 8 survived), and 50% in birds (6 of 12 survived). Our first 8 human WNV patients were published in a peer-reviewed medical journal in 2004 (1). This is sufficient for our treatment to officially exist in both the medical and legal senses, regardless of what the CDC does (or doesn’t) say. We’ve seen that the earlier the treatment is begun, the better the outcome, so public education is absolutely critical—literally, the difference between life and death. Anybody who wants to download our WNV trial protocol can do so for free at any time by clicking on the "West Nile trial" link on our company’s homepage at www.genomed.com. Dave Moskowitz MD CEO & Chief Medical Officer GenoMed, Inc. (Ticker symbol GMED on OTC Pink Sheets) www.genomed.com “The public health company™” 1. Moskowitz DW, Johnson FE. The central role of angiotensin I-converting enzyme in vertebrate pathophysiology. Curr Top Med Chem. 2004;4(13):1433-54. PMID: 15379656 (For PDF file, click on paper #6 at: http://www.genomed.com/index.cfm?action=investor&drill=publications) GenoMed, a genomics-based Disease Management company in St. Louis, has had encouraging results treating West Nile virus encephalitis since 2003.

We’ve had 82% treatment success rate in people (23 of 28 improved), 75% in horses (6 of 8 survived), and 50% in birds (6 of 12 survived). Our first 8 human WNV patients were published in a peer-reviewed medical journal in 2004 (1). This is sufficient for our treatment to officially exist in both the medical and legal senses, regardless of what the CDC does (or doesn’t) say.

We’ve seen that the earlier the treatment is begun, the better the outcome, so public education is absolutely critical—literally, the difference between life and death.

Anybody who wants to download our WNV trial protocol can do so for free at any time by clicking on the “West Nile trial” link on our company’s homepage at http://www.genomed.com.

Dave Moskowitz MD
CEO & Chief Medical Officer
GenoMed, Inc. (Ticker symbol GMED on OTC Pink Sheets)
http://www.genomed.com
“The public health company™”

1. Moskowitz DW, Johnson FE. The central role of angiotensin I-converting enzyme in vertebrate pathophysiology. Curr Top Med Chem. 2004;4(13):1433-54. PMID: 15379656 (For PDF file, click on paper #6 at: http://www.genomed.com/index.cfm?action=investor&drill=publications)

]]>